• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓增生异常综合征中5号染色体缺失的细胞遗传学和分子诊断

Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia.

作者信息

Westbrook C A, Hsu W T, Chyna B, Litvak D, Raza A, Horrigan S K

机构信息

Section of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, 60607-7173, USA.

出版信息

Br J Haematol. 2000 Sep;110(4):847-55. doi: 10.1046/j.1365-2141.2000.02285.x.

DOI:10.1046/j.1365-2141.2000.02285.x
PMID:11054067
Abstract

Deletions of chromosome 5, del(5q), are frequently observed in myelodysplasia (MDS). We evaluated molecular detection of loss of heterozygosity (LOH) as a diagnostic method to detect del(5q) in a series of 60 MDS cases at a single institution. LOH was compared to cytogenetics on the same clinical specimen, resolving ambiguous cases by fluorescent in situ hybridization (FISH) and additional LOH. There was poor concordance between molecular and cytogenetic results, but most discrepancies could be resolved by FISH and additional LOH. Molecular analysis was of low sensitivity because most cases contained a relatively high proportion of cells without del(5q), but it was accurate, while cytogenetics overestimated the proportion of cells with del(5q) and failed to detect some cases with complex rearrangements. Minor clones were detected both by FISH and LOH. Overall, we found an incidence of 23% (14 of 60 cases) for del(5q) in MDS. The results also suggest that there is a high degree of genetic heterogeneity in the cellular population of MDS. Although del(5q) is common in MDS, it may not be present in all cells, leading to diagnostic challenges.

摘要

5号染色体缺失(del(5q))在骨髓增生异常综合征(MDS)中经常可见。我们评估了杂合性缺失(LOH)的分子检测作为一种诊断方法,用于在一家机构的60例MDS病例系列中检测del(5q)。将LOH与同一临床标本的细胞遗传学结果进行比较,通过荧光原位杂交(FISH)和额外的LOH来解决不明确的病例。分子和细胞遗传学结果之间的一致性较差,但大多数差异可以通过FISH和额外的LOH来解决。分子分析的敏感性较低,因为大多数病例中含有相对较高比例的无del(5q)细胞,但它是准确的,而细胞遗传学高估了有del(5q)细胞的比例,并且未能检测到一些具有复杂重排的病例。FISH和LOH均检测到了小克隆。总体而言,我们发现MDS中del(5q)的发生率为23%(60例中的14例)。结果还表明,MDS细胞群体中存在高度的遗传异质性。虽然del(5q)在MDS中很常见,但它可能并非存在于所有细胞中,这导致了诊断上的挑战。

相似文献

1
Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia.骨髓增生异常综合征中5号染色体缺失的细胞遗传学和分子诊断
Br J Haematol. 2000 Sep;110(4):847-55. doi: 10.1046/j.1365-2141.2000.02285.x.
2
A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).一种新的复发性易位,t(5;11)(q35;p15.5),与儿童急性髓系白血病中的5号染色体长臂缺失(del(5q))相关。英国癌症细胞遗传学组(UKCCG)。
Blood. 1999 Jul 15;94(2):773-80.
3
Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.基于聚合酶链反应的急性髓系白血病和骨髓增生异常综合征中del(5q)的诊断确定了一个最小缺失区间。
Blood. 1996 Oct 1;88(7):2665-70.
4
Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia.通过分子细胞遗传学对骨髓增生异常综合征和急性髓系白血病中5q缺失断点的描绘。
Cancer Genet Cytogenet. 2006 May;167(1):66-9. doi: 10.1016/j.cancergencyto.2005.08.003.
5
Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.伴有5号染色体长臂缺失的骨髓增生异常综合征:细胞遗传学检测的指征与策略
Cancer Genet Cytogenet. 2008 Dec;187(2):101-11. doi: 10.1016/j.cancergencyto.2008.08.002.
6
Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.韩国骨髓增生异常综合征中5q缺失和5q-综合征的细胞遗传学特征;荧光原位杂交证实标记染色体为存在间质缺失的5号染色体。
Cancer Genet Cytogenet. 2010 Dec;203(2):193-202. doi: 10.1016/j.cancergencyto.2010.08.007.
7
Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.间期荧光原位杂交不能提高骨髓增生异常综合征中 DEL(5q) 和 DEL(20q) 的检出率。
Anticancer Res. 2011 Mar;31(3):1007-10.
8
Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes.骨髓增生异常综合征伴5号染色体长臂缺失核型患者造血细胞移植后的结局
Br J Haematol. 2003 Dec;123(5):879-85. doi: 10.1046/j.1365-2141.2003.04713.x.
9
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.5q 缺失的骨髓增生异常综合征和急性髓系白血病中 17p 缺失和 TP53 突变的发生率。
Genes Chromosomes Cancer. 2012 Dec;51(12):1086-92. doi: 10.1002/gcc.21993. Epub 2012 Aug 30.
10
Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.荧光原位杂交技术提高了骨髓增生异常综合征中5q31缺失的检测率,而这些病例并无5q-的细胞遗传学证据。
Haematologica. 2008 Jul;93(7):1001-8. doi: 10.3324/haematol.13012.

引用本文的文献

1
Genetic Predisposition to Hematologic Malignancies.血液系统恶性肿瘤的遗传易感性
Cold Spring Harb Perspect Med. 2025 Feb 10. doi: 10.1101/cshperspect.a041585.
2
Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases.NPM2 表达缺失是恶性腹膜间皮瘤的潜在免疫组织化学标志物:一项 92 例的单中心研究。
World J Surg Oncol. 2022 Oct 24;20(1):350. doi: 10.1186/s12957-022-02811-y.
3
An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.
大量肿瘤阵列分析支持核仁磷酸蛋白在乳腺癌中作为肿瘤抑制因子的作用。
Am J Pathol. 2011 Aug;179(2):1004-14. doi: 10.1016/j.ajpath.2011.04.009. Epub 2011 Jun 2.
4
NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype.伴有5q-和复杂核型的骨髓增生异常综合征中的NPM1基因缺失
Haematologica. 2011 May;96(5):784-5. doi: 10.3324/haematol.2010.038620. Epub 2011 Mar 10.
5
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.红系分化特征可预测骨髓增生异常综合征对来那度胺的反应。
PLoS Med. 2008 Feb;5(2):e35. doi: 10.1371/journal.pmed.0050035.
6
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype.间期细胞遗传学检测正常核型骨髓增生异常综合征隐匿性染色体病变的临床重要性。
Leukemia. 2001 Dec;15(12):1841-7. doi: 10.1038/sj.leu.2402293.